These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2017-002698-20||A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)||2019-05-14||due-trials|
|Ongoing||2018-003298-90||Phase 1b/2a study of OPT-302 in combination with aflibercept for persistent central-involved diabetic macular edema||not-yet-due|